(Boursier.com) — Second session of sharp rise for Nanobiotix which soars by nearly 18% to 5 euros late in the morning in Paris. Yesterday, Stifel started monitoring the file at ‘buy’ with a target of 16 euros. “Although NBTXR3 is currently the main asset under development and the short-term growth driver, the company already plans to explore all facets of nanoparticles regardless of the therapeutic area, as evidenced by the launch of the Curadigm platform in 2019 and the recent unveiling of Oocuity, the central platform focused on the nervous system,” explained the broker.
©2024 Boursier.com